Get startedLog in
    Picture of Bayer AG logo

    BAYN — Bayer AG News Story

    0.000.00%
    de flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Bayer Says Iodine-124 Evuzamitide Meets Phase III Endpoints in Cardiac Amyloidosis

    Picture of Bayer AG logoBayer AG
    07/05/2026 07:35
    May 7 (Reuters) - Bayer AG BAYGn.DE:

BAYER AG - INVESTIGATIONAL PET TRACER IODINE 124 EVUZAMITIDE MET PRIMARY ENDPOINTS IN PHASE III STUDY IN PATIENTS SUSPECTED TO HAVE CARDIAC AMYLOIDOSIS

Further company coverage: [BAYGn.DE]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Bayer AG

    See all news